ClinicalTrials.gg
CompletedNCT01703559Updated Oct 30, 2026Results posted

The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances

A Phase 2 interventional study of Phentolamine Mesylate Ophthalmic Solution 1.0% and Phentolamine Mesylate Ophthalmic Solution 0.5% in Night Vision Complaints, Decrease in Night Vision and Disturbance; Vision, Loss, sponsored by Opus Genetics, Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Opus Genetics, Inc · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Sep 2011, registered May 2012).
Updated Oct 8, 2026Results postedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The objectives of this study are:

  • To evaluate the efficacy of phentolamine mesylate 0.5% and 1.0% ophthalmic solution (Nyxol) in the treatment of night vision complaints, including reduced contrast sensitivity
  • To evaluate the ocular and systemic safety of phentolamine mesylate 0.5% and 1.0% ophthalmic solution (Nyxol) compared to its vehicle, a sterile, isotonic, buffered aqueous solution containing mannitol and sodium acetate
Read the detailed description

Randomized, double-masked, multiple dose Phase 2 parallel evaluation of the safety and efficacy of phentolamine mesylate (PM) ophthalmic solution in 60 subjects with severe night vision complaints, evaluating ocular and systemic safety and efficacy following administration of phentolamine mesylate (.05% or 1%) in both eyes for 15 days.

Subjects were randomized into three groups with a 1:1:1 randomization. The groups received either (1) phentolamine mesylate ophthalmic solution 0.5%, (2) phentolamine mesylate ophthalmic solution 1.0%, or (3) placebo, once daily (QD) for 15 days. The treatment period was 15 days, plus 6 additional days over the next 14 days. After 15 days, all subjects were given the opportunity to receive an additional 6 doses of 1.0% phentolamine mesylate to be taken once daily as needed over the next two weeks. There was a post-dosing follow-up evaluation 7 days after the last dose. Study participants completed a night vision questionnaire at pre-treatment and after 15 and 29 days.

Efficacy evaluations included contrast sensitivity (mesopic, with and without glare), mesopic distance high contrast visual acuity (HCVA) and mesopic distance low contrast visual acuity (LCVA). Safety evaluations included photopic distance HCVA, a complete ophthalmic examination and measurement of heart rate and blood pressure.

02

Conditions studied

  • Night Vision Complaints
  • Decrease in Night Vision
  • Disturbance; Vision, Loss

Keywords

  • Glare
  • Starbursts
  • Halos
  • Reduced Contrast Sensitivity
  • Night Vision Disturbances
  • NVD
  • NVDs
03

In context

Lead sponsor

Opus Genetics, Inc is the lead sponsor of 17 studies on the registry; 4 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 to 45 years of age experiencing severe night vision difficulty (as reported subjectively)
  2. 0.3 log improvement at least 1 eye using the Holladay Automated Contrast Sensitivity System (HACSS™) test at 2 of 4 spatial frequencies (3, 6, 12, and 18 cycles per degree) under low and high mesopic room illumination with glare
  3. Photopic visual acuity (corrected or uncorrected) of 20/25 or better
  4. Able and willing to give and comply with all protocol-mandated procedures

Exclusion criteria

Exclusion Criteria:

  1. Cataracts (nuclear sclerosis or anterior subcapsular) of 1+ or greater
  2. Contact lens wear within 4 weeks of enrollment
  3. Ocular trauma within the past 6 months, or ocular surgery or laser treatment within the past 3 months
  4. Refractive surgery or cataract surgery in either eye
  5. Use of ocular medication within 4 weeks of Visit 1
  6. ocular disease (e.g., corneal edema, uveitis, severe keratoconjunctivitis sicca, glaucoma, retinal degenerative disease) which might interfere with the study
  7. Any abnormality preventing reliable applanation tonometry of either eye
  8. Central corneal thickness greater than 600 µ
  9. Known or to PM, or any component of the formulation, or to topical anesthetics.
  10. Contraindications to phentolamine (including history of myocardial infarction, cerebrovascular spasm, cerebrovascular occlusion, coronary insufficiency, angina, or other evidence suggestive of coronary artery disease)
  11. Low blood pressure: systolic \< 100 mm Hg or diastolic \< 60 mm Hg
  12. A history of heart rate abnormalities, such as tachycardia or arrhythmias.
  13. Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia gravis, hepatic, renal, cardiovascular, or endocrine disorders) which might interfere with the study
  14. Use of any systemic alpha adrenergic antagonists up to 4 weeks prior to screening or during the study
  15. Changes of systemic medication that could have a substantial effect on ocular autonomic pupil tone 4 weeks prior to screening, or anticipated during the study
  16. Participation in any study within the past 30 days
  17. Women of who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of . An adult woman is considered to be of childbearing potential unless she is 1 year or 3 months post-surgical sterilization. All females of childbearing potential must have a negative serum pregnancy test result at the screening examination and must not intend to become pregnant during the study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Administered once daily in both eyes for 15 days

    Other: Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)

  • Experimental
    Phentolamine Mesylate Ophthalmic Solution 0.5%

    Administered once daily in both eyes for 15 days

    Drug: Phentolamine Mesylate Ophthalmic Solution 0.5%

  • Experimental
    Phentolamine Mesylate Ophthalmic Solution 1.0%

    Administered once daily in both eyes for 15 days

    Drug: Phentolamine Mesylate Ophthalmic Solution 1.0%

Interventions

  • Phentolamine mesylate (Nyxol) ophthalmic solution 1.0% is a non-selective alpha-1 and alpha-2 adrenergic antagonist

    Also known as: Nyxol®, Nyxol

  • Phentolamine mesylate (Nyxol) ophthalmic solution 0.5% is a non-selective alpha-1 and alpha-2 adrenergic antagonist

    Also known as: Nyxol®, Nyxol

  • OtherPhentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)

    Placebo (vehicle) is a sterile, isotonic, buffered aqueous solution containing mannitol and sodium acetate

06

What researchers measure

Primary outcomes

  1. Proportion of Eyes With ≥ 0.3 Log Increase in Mesopic Contrast Sensitivities for at Least 2 HACSS Frequencies

    Proportion of eyes with an increase ≥ 0.3 log (2 or more patches) in mesopic contrast sensitivity with glare at two or more frequencies at 1.5, 3, 6, 12, and 18 cycles per degree, measured with the HACSS methodology (categorical analysis)

    Time frame: Postdose Day 1, 4, 8, 15, and Day 15 (LOCF=Last Observation Carried Forward)

Secondary outcomes

  1. Pupil Diameter - Change From Day 1 Pre-Dose Baseline

    Time frame: Day 1 post-dose and Days 4, 8, and 15

  2. Mean Mesopic Contrast Sensitivity With Glare at Frequencies of 1.5, 3, 6, 12, and 18 Cycles Per Degree, Measured With the HACSS Methodology in LogCS Scale - Change From Day 1 Pre-Dose Baseline

    At screening, contralateral illumination contrast sensitivity (HACSS) was measured to determine subject/eye eligibility. The Day 1 predose HACSS LogCS value served as the baseline for assessing improvement. At each post-dose visit (Days 1, 4, 8, 15), eyes with an improvement of at least 0.3 LogCS in mesopic contrast sensitivity with glare compared to baseline were summarized across all 5 frequencies (1.5, 3, 6, 12, and 18 cycles per degree). The Log CS (Logarithmic Contrast Sensitivity) scale measures how faintly an object can be distinguished from its background, calculated as the logarithm of contrast sensitivity (CS = 1 ÷ contrast threshold). Higher values indicate the ability to see highly faded, low-contrast images.

    Time frame: 15 Days

  3. Mesopic Contrast Sensitivity Without Glare at 1 or More Frequencies at 1.5, 3, 6, 12, and 18 Cycles Per Degree, Measured With the HACSS Methodology in LogCS Scale - Mean Change From Day 1 Pre-Dose Baseline

    At screening, contralateral illumination contrast sensitivity (HACSS) was measured to determine subject/eye eligibility. The Day 1 predose HACSS LogCS value served as the baseline for assessing improvement. Only eyes with at least 0.3 LogCS improvement at 2 or more frequencies were counted as showing overall improvement. At each postdose visit (Days 1, 4, 8, 15), eyes with an improvement of at least 0.3 LogCS in mesopic contrast sensitivity with glare compared to baseline were across all 5 frequencies 1.5, 3, 6, 12, and 18 cycles per degree.

    Time frame: Day 1 post-dose and Days 4, 8, and 15

  4. Mesopic Distance High Contrast Visual Acuity (HCVA), Measured With Electronic Early Treatment Diabetic Retinopathy Study (eETDRS) Charts - Change From Day 1 Pre-Dose Baseline

    Time frame: Day 1 post-dose and Days 4, 8, and 15

  5. Mesopic Distance Low Contrast Visual Acuity (LCVA), Measured With eETDRS Charts - Change From Day 1 Pre-Dose Baseline

    Time frame: Day 1 post-dose and Days 4, 8, and 15

  6. Subjective Evaluations of Vision (NEI Vision Function) at Follow-up (Day 32)

    NEI visual functioning questionnaire-25 (VFQ-25) Adapted for Dim Light Vision was conducted at the follow-up visit on Day 32. The frequency of categorical answers was summarized by treatment for each question. The questions are on a scale that ranges from 1-2, 1-2, 1-5, or 1-6 with 1 being the best outcome and 6 being the worst. Q14, Q15: 1-2; Q1, Q3, Q16, Q17, Q18, Q19, Q20, Q21, Q22, Q23: 1-5; Q2, Q4, Q5, Q6, Q7, Q8, Q9, Q10, Q11, Q12, Q13, Q14a, Q14b, Q14c, Q15, Q15a: 1-6. Questions 2 through 15a on the VFQ related to the subject's assessment of how much difficulty, if any, the subject has doing certain activities in dim light or at night, particularly driving (Questions 14c, 15, and 15a); the remaining questions related to how things the subject does may be affected by their vision in dim light or at night.

    Time frame: Day 32

07

Results

Posted Oct 8, 2026

Participant flow

Randomized Treatment Period
Participant flow — Randomized Treatment Period
MilestonePlaceboPhentolamine Mesylate Ophthalmic Solution 0.5%Phentolamine Mesylate Ophthalmic Solution 1.0%
Started202020
Completed182020
Not completed200
Optional 1.0% Phentolamine Period
Participant flow — Optional 1.0% Phentolamine Period
MilestonePlaceboPhentolamine Mesylate Ophthalmic Solution 0.5%Phentolamine Mesylate Ophthalmic Solution 1.0%
Started182020
Completed181920
Not completed010

Outcome measures

PrimaryProportion of Eyes With ≥ 0.3 Log Increase in Mesopic Contrast Sensitivities for at Least 2 HACSS Frequencies

Proportion of eyes with an increase ≥ 0.3 log (2 or more patches) in mesopic contrast sensitivity with glare at two or more frequencies at 1.5, 3, 6, 12, and 18 cycles per degree, measured with the HACSS methodology (categorical analysis)

Time frame:
Postdose Day 1, 4, 8, 15, and Day 15 (LOCF=Last Observation Carried Forward)
Reported as:
Count of units · Eyes
Proportion of Eyes With ≥ 0.3 Log Increase in Mesopic Contrast Sensitivities for at Least 2 HACSS Frequencies
EyesPlaceboPhentolamine Mesylate Ophthalmic Solution 0.5%Phentolamine Mesylate Ophthalmic Solution 1.0%
Day 1 Postdose583
Day 4 Postdose674
Day 8 Postdose7109
Day 15 Postdose61511
Day 15 Postdose (LOCF)71511
SecondaryPupil Diameter - Change From Day 1 Pre-Dose Baseline
Time frame:
Day 1 post-dose and Days 4, 8, and 15
Reported as:
Mean · mm
Pupil Diameter - Change From Day 1 Pre-Dose Baseline
mmPlaceboPhentolamine Mesylate Ophthalmic Solution 0.5%Phentolamine Mesylate Ophthalmic Solution 1.0%
Day 1 Postdose0.16 ± 0.828-0.82 ± 0.829-1.07 ± 0.651
Day 4 Postdose0.02 ± 0.833-1.17 ± 0.751-1.22 ± 0.863
Day 8 Postdose-0.07 ± 0.969-0.92 ± 0.956-0.93 ± 0.736
Day 15 Postdose0.17 ± 1.232-0.51 ± 0.639-0.81 ± 0.846
SecondaryMean Mesopic Contrast Sensitivity With Glare at Frequencies of 1.5, 3, 6, 12, and 18 Cycles Per Degree, Measured With the HACSS Methodology in LogCS Scale - Change From Day 1 Pre-Dose Baseline

At screening, contralateral illumination contrast sensitivity (HACSS) was measured to determine subject/eye eligibility. The Day 1 predose HACSS LogCS value served as the baseline for assessing improvement. At each post-dose visit (Days 1, 4, 8, 15), eyes with an improvement of at least 0.3 LogCS in mesopic contrast sensitivity with glare compared to baseline were summarized across all 5 frequencies (1.5, 3, 6, 12, and 18 cycles per degree). The Log CS (Logarithmic Contrast Sensitivity) scale measures how faintly an object can be distinguished from its background, calculated as the logarithm of contrast sensitivity (CS = 1 ÷ contrast threshold). Higher values indicate the ability to see highly faded, low-contrast images.

Time frame:
15 Days
Reported as:
Mean · Log CS
Mean Mesopic Contrast Sensitivity With Glare at Frequencies of 1.5, 3, 6, 12, and 18 Cycles Per Degree, Measured With the HACSS Methodology in LogCS Scale - Change From Day 1 Pre-Dose Baseline
Log CSPlaceboPhentolamine Mesylate Ophthalmic Solution 0.5%Phentolamine Mesylate Ophthalmic Solution 1.0%
Day 1 post-dose, 1.50.00 ± 0.2340.01 ± 0.257-0.09 ± 0.310
Day 4 post-dose, 1.5-0.03 ± 0.388-0.02 ± 0.293-0.06 ± 0.288
Day 8 post-dose, 1.5-0.11 ± 0.3430.02 ± 0.3850.04 ± 0.297
Day 15 post-dose, 1.5-0.08 ± 0.351-0.01 ± 0.3910.06 ± 0.310
Day 1 post-dose, 3.0-0.08 ± 0.2220.01 ± 0.202-0.09 ± 0.230
Day 4 post-dose, 3.0-0.08 ± 0.3230.01 ± 0.282-0.01 ± 0.211
Day 8 post-dose, 3.0-0.08 ± 0.3240.04 ± 0.3250.03 ± 0.256
Day 15 post-dose, 3.0-0.10 ± 0.3620.03 ± 0.316-0.01 ± 0.285
Day 1 post-dose, 6.00.03 ± 0.2780.05 ± 0.163-0.11 ± 0.292
Day 4 post-dose, 6.0-0.02 ± 0.3200.03 ± 0.237-0.05 ± 0.296
Day 8 post-dose, 6.0-0.06 ± 0.3410.04 ± 0.2760.00 ± 0.310
Day 15 post-dose, 6.0-0.05 ± 0.3990.03 ± 0.378-0.02 ± 0.336
Day 1 post-dose, 12.0-0.01 ± 0.2870.03 ± 0.212-0.13 ± 0.335
Day 4 post-dose, 12.0-0.04 ± 0.2730.02 ± 0.298-0.10 ± 0.397
Day 8 post-dose, 12.0-0.02 ± 0.2940.05 ± 0.317-0.03 ± 0.341
Day 15 post-dose, 12.0-0.04 ± 0.3200.01 ± 0.337-0.01 ± 0.348
Day 1 post-dose, 18.0-0.04 ± 0.2140.00 ± 0.333-0.05 ± 0.275
Day 4 post-dose, 18.0-0.05 ± 0.236-0.05 ± 0.271-0.02 ± 0.376
Day 8 post-dose, 18.0-0.01 ± 0.255-0.01 ± 0.3770.02 ± 0.343
Day 15 post-dose, 18.00.00 ± 0.2890.11 ± 0.3680.03 ± 0.325
SecondaryMesopic Contrast Sensitivity Without Glare at 1 or More Frequencies at 1.5, 3, 6, 12, and 18 Cycles Per Degree, Measured With the HACSS Methodology in LogCS Scale - Mean Change From Day 1 Pre-Dose Baseline

At screening, contralateral illumination contrast sensitivity (HACSS) was measured to determine subject/eye eligibility. The Day 1 predose HACSS LogCS value served as the baseline for assessing improvement. Only eyes with at least 0.3 LogCS improvement at 2 or more frequencies were counted as showing overall improvement. At each postdose visit (Days 1, 4, 8, 15), eyes with an improvement of at least 0.3 LogCS in mesopic contrast sensitivity with glare compared to baseline were across all 5 frequencies 1.5, 3, 6, 12, and 18 cycles per degree.

Time frame:
Day 1 post-dose and Days 4, 8, and 15
Reported as:
Mean · Log CS
Mesopic Contrast Sensitivity Without Glare at 1 or More Frequencies at 1.5, 3, 6, 12, and 18 Cycles Per Degree, Measured With the HACSS Methodology in LogCS Scale - Mean Change From Day 1 Pre-Dose Baseline
Log CSPlaceboPhentolamine Mesylate Ophthalmic Solution 0.5%Phentolamine Mesylate Ophthalmic Solution 1.0%
Day 1 Postdose, 1.50.00 ± 0.189-0.02 ± 0.200-0.14 ± 0.222
Day 4 Postdose, 1.5-0.06 ± 0.316-0.03 ± 0.272-0.04 ± 0.231
Day 8 Postdose, 1.5-0.06 ± 0.276-0.01 ± 0.347-0.02 ± 0.307
Day 15 Postdose, 1.5-0.03 ± 0.4040.02 ± 0.313-0.02 ± 0.275
Day 1 Postdose, 3.0-0.03 ± 0.2290.00 ± 0.156-0.06 ± 0.234
Day 4 Postdose, 3.0-0.08 ± 0.3690.01 ± 0.2080.02 ± 0.203
Day 8 Postdose, 3.0-0.06 ± 0.345-0.03 ± 0.3190.00 ± 0.236
Day 15 Postdose, 3.0-0.07 ± 0.353-0.01 ± 0.2750.01 ± 0.250
Day 1 Postdose, 6.0-0.01 ± 0.2160.01 ± 0.171-0.02 ± 0.170
Day 4 Postdose, 6.0-0.06 ± 0.3760.01 ± 0.2460.00 ± 0.202
Day 8 Postdose, 6.0-0.03 ± 0.3170.03 ± 0.2380.05 ± 0.202
Day 15 Postdose, 6.0-0.06 ± 0.3560.05 ± 0.2270.02 ± 0.218
Day 1 Postdose, 12.0-0.05 ± 0.225-0.01 ± 0.247-0.04 ± 0.196
Day 4 Postdose, 12.0-0.10 ± 0.280-0.02 ± 0.2970.03 ± 0.271
Day 8 Postdose, 12.0-0.01 ± 0.3120.01 ± 0.3700.05 ± 0.229
Day 15 Postdose, 12.0-0.08 ± 0.3250.08 ± 0.3810.03 ± 0.227
Day 1 Postdose, 18.0-0.02 ± 0.234-0.03 ± 0.2460.04 ± 0.245
Day 4 Postdose, 18.0-0.04 ± 0.238-0.08 ± 0.3190.04 ± 0.313
Day 8 Postdose, 18.00.03 ± 0.270-0.03 ± 0.3780.02 ± 0.292
Day 15 Postdose, 18.0-0.01 ± 0.2850.13 ± 0.3720.04 ± 0.285
SecondaryMesopic Distance High Contrast Visual Acuity (HCVA), Measured With Electronic Early Treatment Diabetic Retinopathy Study (eETDRS) Charts - Change From Day 1 Pre-Dose Baseline
Time frame:
Day 1 post-dose and Days 4, 8, and 15
Reported as:
Mean · ETDRS Letter Score
Mesopic Distance High Contrast Visual Acuity (HCVA), Measured With Electronic Early Treatment Diabetic Retinopathy Study (eETDRS) Charts - Change From Day 1 Pre-Dose Baseline
ETDRS Letter ScorePlaceboPhentolamine Mesylate Ophthalmic Solution 0.5%Phentolamine Mesylate Ophthalmic Solution 1.0%
Day 1 Postdose1.175 ± 3.72722.025 ± 9.35480.700 ± 4.0077
Day 4 Postdose2.025 ± 4.64923.350 ± 9.84382.600 ± 3.6006
Day 8 Postdose2.050 ± 4.56833.895 ± 9.98862.825 ± 3.9281
Day 15 Postdose2.421 ± 4.85824.947 ± 9.39513.825 ± 6.0123
SecondaryMesopic Distance Low Contrast Visual Acuity (LCVA), Measured With eETDRS Charts - Change From Day 1 Pre-Dose Baseline
Time frame:
Day 1 post-dose and Days 4, 8, and 15
Reported as:
Mean · ETDRS Letter Score
Mesopic Distance Low Contrast Visual Acuity (LCVA), Measured With eETDRS Charts - Change From Day 1 Pre-Dose Baseline
ETDRS Letter ScorePlaceboPhentolamine Mesylate Ophthalmic Solution 0.5%Phentolamine Mesylate Ophthalmic Solution 1.0%
Day 1 Postdose1.750 ± 4.81850.975 ± 5.44191.325 ± 4.8272
Day 4 Postdose3.100 ± 6.11351.350 ± 6.02795.825 ± 7.1607
Day 8 Postdose3.650 ± 6.07031.421 ± 7.38757.050 ± 7.3063
Day 15 Postdose4.838 ± 6.44005.184 ± 7.82887.100 ± 9.1085
SecondarySubjective Evaluations of Vision (NEI Vision Function) at Follow-up (Day 32)

NEI visual functioning questionnaire-25 (VFQ-25) Adapted for Dim Light Vision was conducted at the follow-up visit on Day 32. The frequency of categorical answers was summarized by treatment for each question. The questions are on a scale that ranges from 1-2, 1-2, 1-5, or 1-6 with 1 being the best outcome and 6 being the worst. Q14, Q15: 1-2; Q1, Q3, Q16, Q17, Q18, Q19, Q20, Q21, Q22, Q23: 1-5; Q2, Q4, Q5, Q6, Q7, Q8, Q9, Q10, Q11, Q12, Q13, Q14a, Q14b, Q14c, Q15, Q15a: 1-6. Questions 2 through 15a on the VFQ related to the subject's assessment of how much difficulty, if any, the subject has doing certain activities in dim light or at night, particularly driving (Questions 14c, 15, and 15a); the remaining questions related to how things the subject does may be affected by their vision in dim light or at night.

Time frame:
Day 32
Reported as:
Count of participants · Participants
Subjective Evaluations of Vision (NEI Vision Function) at Follow-up (Day 32)
ParticipantsPhentolamine Mesylate Ophthalmic Solution 1.0%
Q1: In general, would you say your overall health is: — 120
Q1: In general, would you say your overall health is: — 223
Q1: In general, would you say your overall health is: — 314
Q1: In general, would you say your overall health is: — 41
Q1: In general, would you say your overall health is: — 50
Q1: In general, would you say your overall health is: — 60
Q2: At the present time, would you say your eyesight using both eyes is: — 15
Q2: At the present time, would you say your eyesight using both eyes is: — 219
Q2: At the present time, would you say your eyesight using both eyes is: — 328
Q2: At the present time, would you say your eyesight using both eyes is: — 46
Q2: At the present time, would you say your eyesight using both eyes is: — 50
Q2: At the present time, would you say your eyesight using both eyes is: — 60
Q3: How much of the time do you worry about your eyesight? — 14
Q3: How much of the time do you worry about your eyesight? — 223
Q3: How much of the time do you worry about your eyesight? — 325
Q3: How much of the time do you worry about your eyesight? — 46
Q3: How much of the time do you worry about your eyesight? — 50
Q3: How much of the time do you worry about your eyesight? — 60
Q4: How much difficulty do you have reading ordinary print in newspapers? Would you say you have: — 14
Q4: How much difficulty do you have reading ordinary print in newspapers? Would you say you have: — 225
Q4: How much difficulty do you have reading ordinary print in newspapers? Would you say you have: — 320
Q4: How much difficulty do you have reading ordinary print in newspapers? Would you say you have: — 49
Q4: How much difficulty do you have reading ordinary print in newspapers? Would you say you have: — 50
Q4: How much difficulty do you have reading ordinary print in newspapers? Would you say you have: — 60
Q5: How much difficulty do you have doing work or hobbies that require you to see well up close... — 113
Q5: How much difficulty do you have doing work or hobbies that require you to see well up close... — 220
Q5: How much difficulty do you have doing work or hobbies that require you to see well up close... — 321
Q5: How much difficulty do you have doing work or hobbies that require you to see well up close... — 44
Q5: How much difficulty do you have doing work or hobbies that require you to see well up close... — 50
Q5: How much difficulty do you have doing work or hobbies that require you to see well up close... — 60
Q6: Because of your eyesight, how much difficulty do you have finding something on a crowded shelf? — 112
Q6: Because of your eyesight, how much difficulty do you have finding something on a crowded shelf? — 227
Q6: Because of your eyesight, how much difficulty do you have finding something on a crowded shelf? — 316
Q6: Because of your eyesight, how much difficulty do you have finding something on a crowded shelf? — 43
Q6: Because of your eyesight, how much difficulty do you have finding something on a crowded shelf? — 50
Q6: Because of your eyesight, how much difficulty do you have finding something on a crowded shelf? — 60
Q7: How much difficulty do you have reading street signs or the names of stores? — 16
Q7: How much difficulty do you have reading street signs or the names of stores? — 222
Q7: How much difficulty do you have reading street signs or the names of stores? — 323
Q7: How much difficulty do you have reading street signs or the names of stores? — 47
Q7: How much difficulty do you have reading street signs or the names of stores? — 50
Q7: How much difficulty do you have reading street signs or the names of stores? — 60
Q8: Because of your eyesight, how much difficulty do you have going down steps, stairs, or curbs... — 120
Q8: Because of your eyesight, how much difficulty do you have going down steps, stairs, or curbs... — 222
Q8: Because of your eyesight, how much difficulty do you have going down steps, stairs, or curbs... — 315
Q8: Because of your eyesight, how much difficulty do you have going down steps, stairs, or curbs... — 41
Q8: Because of your eyesight, how much difficulty do you have going down steps, stairs, or curbs... — 50
Q8: Because of your eyesight, how much difficulty do you have going down steps, stairs, or curbs... — 60
Q9: Because of your eyesight, how much difficulty do you have noticing objects off to the side... — 114
Q9: Because of your eyesight, how much difficulty do you have noticing objects off to the side... — 223
Q9: Because of your eyesight, how much difficulty do you have noticing objects off to the side... — 318
Q9: Because of your eyesight, how much difficulty do you have noticing objects off to the side... — 43
Q9: Because of your eyesight, how much difficulty do you have noticing objects off to the side... — 50
Q9: Because of your eyesight, how much difficulty do you have noticing objects off to the side... — 60
Q10: Because of your eyesight, how much difficulty do you have seeing how people react to things... — 124
Q10: Because of your eyesight, how much difficulty do you have seeing how people react to things... — 220
Q10: Because of your eyesight, how much difficulty do you have seeing how people react to things... — 312
Q10: Because of your eyesight, how much difficulty do you have seeing how people react to things... — 42
Q10: Because of your eyesight, how much difficulty do you have seeing how people react to things... — 50
Q10: Because of your eyesight, how much difficulty do you have seeing how people react to things... — 60
Q11: Because of your eyesight, how much difficulty do you have picking out and matching your own... — 130
Q11: Because of your eyesight, how much difficulty do you have picking out and matching your own... — 219
Q11: Because of your eyesight, how much difficulty do you have picking out and matching your own... — 37
Q11: Because of your eyesight, how much difficulty do you have picking out and matching your own... — 42
Q11: Because of your eyesight, how much difficulty do you have picking out and matching your own... — 50
Q11: Because of your eyesight, how much difficulty do you have picking out and matching your own... — 60
Q12: Because of your eyesight, how much difficulty do you have visiting with people in their homes.. — 132
Q12: Because of your eyesight, how much difficulty do you have visiting with people in their homes.. — 217
Q12: Because of your eyesight, how much difficulty do you have visiting with people in their homes.. — 37
Q12: Because of your eyesight, how much difficulty do you have visiting with people in their homes.. — 42
Q12: Because of your eyesight, how much difficulty do you have visiting with people in their homes.. — 50
Q12: Because of your eyesight, how much difficulty do you have visiting with people in their homes.. — 60
Q13: Because of your eyesight, how much difficulty do you have going out to see movies, plays, or... — 126
Q13: Because of your eyesight, how much difficulty do you have going out to see movies, plays, or... — 217
Q13: Because of your eyesight, how much difficulty do you have going out to see movies, plays, or... — 313
Q13: Because of your eyesight, how much difficulty do you have going out to see movies, plays, or... — 42
Q13: Because of your eyesight, how much difficulty do you have going out to see movies, plays, or... — 50
Q13: Because of your eyesight, how much difficulty do you have going out to see movies, plays, or... — 60
Q14: I'd like to ask about driving a car. Are you currently driving , at least once in a while? — 153
Q14: I'd like to ask about driving a car. Are you currently driving , at least once in a while? — 25
Q14: I'd like to ask about driving a car. Are you currently driving , at least once in a while? — 30
Q14: I'd like to ask about driving a car. Are you currently driving , at least once in a while? — 40
Q14: I'd like to ask about driving a car. Are you currently driving , at least once in a while? — 50
Q14: I'd like to ask about driving a car. Are you currently driving , at least once in a while? — 60
Q14a: IF NO: Have you never driven a car or have you given up driving? — 11
Q14a: IF NO: Have you never driven a car or have you given up driving? — 24
Q14a: IF NO: Have you never driven a car or have you given up driving? — 30
Q14a: IF NO: Have you never driven a car or have you given up driving? — 40
Q14a: IF NO: Have you never driven a car or have you given up driving? — 50
Q14a: IF NO: Have you never driven a car or have you given up driving? — 60
Q14b: IF GAVE UP DRIVING: Was that mainly because of your eyesight, mainly for some other reason... — 12
Q14b: IF GAVE UP DRIVING: Was that mainly because of your eyesight, mainly for some other reason... — 21
Q14b: IF GAVE UP DRIVING: Was that mainly because of your eyesight, mainly for some other reason... — 31
Q14b: IF GAVE UP DRIVING: Was that mainly because of your eyesight, mainly for some other reason... — 40
Q14b: IF GAVE UP DRIVING: Was that mainly because of your eyesight, mainly for some other reason... — 50
Q14b: IF GAVE UP DRIVING: Was that mainly because of your eyesight, mainly for some other reason... — 60
Q14c: IF CURRENTLY DRIVING: How much difficulty do you have driving during the daytime in... — 116
Q14c: IF CURRENTLY DRIVING: How much difficulty do you have driving during the daytime in... — 227
Q14c: IF CURRENTLY DRIVING: How much difficulty do you have driving during the daytime in... — 310
Q14c: IF CURRENTLY DRIVING: How much difficulty do you have driving during the daytime in... — 40
Q14c: IF CURRENTLY DRIVING: How much difficulty do you have driving during the daytime in... — 50
Q14c: IF CURRENTLY DRIVING: How much difficulty do you have driving during the daytime in... — 60
Q15: How much difficulty do you have driving at night? Would you say you have: — 15
Q15: How much difficulty do you have driving at night? Would you say you have: — 218
Q15: How much difficulty do you have driving at night? Would you say you have: — 322
Q15: How much difficulty do you have driving at night? Would you say you have: — 48
Q15: How much difficulty do you have driving at night? Would you say you have: — 50
Q15: How much difficulty do you have driving at night? Would you say you have: — 60
Q15a: How much difficulty do you have driving in difficult conditions, such as in bad weather... — 12
Q15a: How much difficulty do you have driving in difficult conditions, such as in bad weather... — 223
Q15a: How much difficulty do you have driving in difficult conditions, such as in bad weather... — 314
Q15a: How much difficulty do you have driving in difficult conditions, such as in bad weather... — 413
Q15a: How much difficulty do you have driving in difficult conditions, such as in bad weather... — 50
Q15a: How much difficulty do you have driving in difficult conditions, such as in bad weather... — 60
Q16: Do you accomplish less than you would like because of your vision? — 10
Q16: Do you accomplish less than you would like because of your vision? — 27
Q16: Do you accomplish less than you would like because of your vision? — 316
Q16: Do you accomplish less than you would like because of your vision? — 424
Q16: Do you accomplish less than you would like because of your vision? — 511
Q16: Do you accomplish less than you would like because of your vision? — 60
Q17: Are you limited in how long you can work or do other activities because of your vision? — 10
Q17: Are you limited in how long you can work or do other activities because of your vision? — 26
Q17: Are you limited in how long you can work or do other activities because of your vision? — 316
Q17: Are you limited in how long you can work or do other activities because of your vision? — 417
Q17: Are you limited in how long you can work or do other activities because of your vision? — 519
Q17: Are you limited in how long you can work or do other activities because of your vision? — 60
Q18: I stay home most of the time because of my eyesight... — 11
Q18: I stay home most of the time because of my eyesight... — 211
Q18: I stay home most of the time because of my eyesight... — 38
Q18: I stay home most of the time because of my eyesight... — 418
Q18: I stay home most of the time because of my eyesight... — 520
Q18: I stay home most of the time because of my eyesight... — 60
Q19: I feel frustrated a lot of the time because of my eyesight... — 12
Q19: I feel frustrated a lot of the time because of my eyesight... — 222
Q19: I feel frustrated a lot of the time because of my eyesight... — 38
Q19: I feel frustrated a lot of the time because of my eyesight... — 410
Q19: I feel frustrated a lot of the time because of my eyesight... — 516
Q19: I feel frustrated a lot of the time because of my eyesight... — 60
Q20: I have much less control over what I do, because of my eyesight.... — 10
Q20: I have much less control over what I do, because of my eyesight.... — 211
Q20: I have much less control over what I do, because of my eyesight.... — 313
Q20: I have much less control over what I do, because of my eyesight.... — 420
Q20: I have much less control over what I do, because of my eyesight.... — 514
Q20: I have much less control over what I do, because of my eyesight.... — 60
Q21: Because of my eyesight, I have to rely too much on what other people tell me. — 10
Q21: Because of my eyesight, I have to rely too much on what other people tell me. — 213
Q21: Because of my eyesight, I have to rely too much on what other people tell me. — 39
Q21: Because of my eyesight, I have to rely too much on what other people tell me. — 416
Q21: Because of my eyesight, I have to rely too much on what other people tell me. — 520
Q21: Because of my eyesight, I have to rely too much on what other people tell me. — 60
Q22: I need a lot of help from others because of my eyesight.. — 12
Q22: I need a lot of help from others because of my eyesight.. — 29
Q22: I need a lot of help from others because of my eyesight.. — 38
Q22: I need a lot of help from others because of my eyesight.. — 412
Q22: I need a lot of help from others because of my eyesight.. — 527
Q22: I need a lot of help from others because of my eyesight.. — 60
Q23: I worry about doing things that will embarrass myself or others, because of my eyesight. — 10
Q23: I worry about doing things that will embarrass myself or others, because of my eyesight. — 29
Q23: I worry about doing things that will embarrass myself or others, because of my eyesight. — 38
Q23: I worry about doing things that will embarrass myself or others, because of my eyesight. — 413
Q23: I worry about doing things that will embarrass myself or others, because of my eyesight. — 528
Q23: I worry about doing things that will embarrass myself or others, because of my eyesight. — 60

Adverse events

Collected over Adverse events were monitored throughout the study (from time of admission to the clinic through the Follow-up visit on Day 32) until resolution.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/20 (0%)0/20 (0%)15/20 (75%)
Phentolamine Mesylate Ophthalmic Solution 0.5%0/20 (0%)0/20 (0%)16/20 (80%)
Phentolamine Mesylate Ophthalmic Solution 1.0%0/20 (0%)0/20 (0%)17/20 (85%)
Period 2 - 1.0% Phentolamine Mesylate Ophthalmic Solution0/57 (0%)0/57 (0%)13/57 (22.8%)
Most frequent other events
Showing 10 of 41
Most frequent other events
EventPlaceboPhentolamine Mesylate Ophthalmic Solution 0.5%Phentolamine Mesylate Ophthalmic Solution 1.0%Period 2 - 1.0% Phentolamine Mesylate Ophthalmic Solution
Eye irritationEye disorders3/207/2010/205/57
Conjunctival hyperaemiaEye disorders0/204/208/200/57
Product taste abnormalGeneral disorders2/202/207/202/57
HeadacheNervous system disorders6/204/204/203/57
Eye pruritusEye disorders3/205/202/201/57
Dry eyeEye disorders1/204/201/200/57
DysgeusiaNervous system disorders0/204/202/200/57
PhotophobiaEye disorders0/200/203/201/57
Abnormal sensation in eyeEye disorders1/202/201/200/57
AsthenopiaEye disorders2/201/201/200/57

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboPhentolamine Mesylate Ophthalmic Solution 0.5%Phentolamine Mesylate Ophthalmic Solution 1.0%Total
Mean34.5 ± 8.0132.3 ± 7.2935.1 ± 6.6034.0 ± 7.30
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboPhentolamine Mesylate Ophthalmic Solution 0.5%Phentolamine Mesylate Ophthalmic Solution 1.0%Total
Female12101335
Male810725
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboPhentolamine Mesylate Ophthalmic Solution 0.5%Phentolamine Mesylate Ophthalmic Solution 1.0%Total
American Indian or Alaska Native0101
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American3339
White15161748
More than one race0000
Unknown or Not Reported2002
Central Corneal Thickness (Right Eye)
Central Corneal Thickness (Right Eye)(um)PlaceboPhentolamine Mesylate Ophthalmic Solution 0.5%Phentolamine Mesylate Ophthalmic Solution 1.0%Total
Mean550.5 ± 29.60556.0 ± 29.44550.4 ± 35.54552.3 ± 31.23
Central Corneal Thickness (Left Eye)
Central Corneal Thickness (Left Eye)(um)PlaceboPhentolamine Mesylate Ophthalmic Solution 0.5%Phentolamine Mesylate Ophthalmic Solution 1.0%Total
Mean552.0 ± 25.51554.5 ± 26.84551.3 ± 34.64552.6 ± 28.81
08

Study locations

1 site
  • Celerion
    Phoenix, Arizona 67230, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2011 to primary completion in Apr 2012, 7 months.

Results were first posted in Oct 2026, 14 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2012
First posted
Oct 10, 2012
StartActual
Sep 9, 2011
Primary completionActual
Apr 16, 2012
CompletionActual
Apr 30, 2012
Results first posted
Oct 8, 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 8, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameProportion of Eyes With ≥ 0.3 Log Increase in Mesopic Contrast Sensitivities for at Least 2 HACSS FrequenciesDays 1, 4, 8, 15, and 32 → Postdose Day 1, 4, 8, 15, and Day 15 (LOCF=Last Observation Carried Forward)
  • DescriptionProportion of Eyes With ≥ 0.3 Log Increase in Mesopic Contrast Sensitivities for at Least 2 HACSS Frequencies: how it is measured was reworded
Oct 8, 2026
Secondary outcomes
5 edited, 1 added, 1 removed
What changed in the outcomes
  • EditedPupil Diameter - Change fromFrom Day 1 Pre-Dose BaselineTime frame: Day 1 post-dose and Days 4, 8, and 15
  • EditedMean Mesopic Contrast Sensitivity withWith Glare at 1 or More Frequencies atof 1.5, 3, 6, 12, and 18 Cycles Per Degree, Measured withWith the HACSS Methodology in LogCS Scale - Change fromFrom Day 1 Pre-Dose BaselineTime frame: Day 1 post-dose and Days 4, 8, and 15 → 15 Days
  • EditedMesopic Contrast Sensitivity withoutWithout Glare at 1 or More Frequencies at 1.5, 3, 6, 12, and 18 Cycles Per Degree, Measured withWith the HACSS Methodology in LogCS Scale - Mean Change fromFrom Day 1 Pre-Dose BaselineTime frame: Day 1 post-dose and Days 4, 8, and 15
  • EditedMesopic Distance High Contrast Visual Acuity (HCVA), Measured withWith Electronic Early Treatment Diabetic Retinopathy Study (eETDRS) Charts - Change fromFrom Day 1 Pre-Dose BaselineTime frame: Day 1 post-dose and Days 4, 8, and 15
  • EditedMesopic Distance Low Contrast Visual Acuity (LCVA), Measured withWith eETDRS Charts - Change fromFrom Day 1 Pre-Dose BaselineTime frame: Day 1 post-dose and Days 4, 8, and 15
  • AddedSubjective Evaluations of Vision (NEI Vision Function) at Follow-up (Day 32)Time frame: Day 32
  • Removedother outcomeSubjective Evaluations of Vision (NEI Vision Function) - Change from Day 15Time frame: Day 32
Oct 8, 2026
Show all 2 updates
  1. Oct 30, 2026
    Minor edits only
    + 1 other change: contact details
  2. Oct 8, 2026
    Results posted
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameProportion of Eyes With ≥ 0.3 Log Increase in Mesopic Contrast Sensitivities for at Least 2 HACSS FrequenciesDays 1, 4, 8, 15, and 32 → Postdose Day 1, 4, 8, 15, and Day 15 (LOCF=Last Observation Carried Forward)
    • DescriptionProportion of Eyes With ≥ 0.3 Log Increase in Mesopic Contrast Sensitivities for at Least 2 HACSS Frequencies: how it is measured was reworded
    Secondary outcomes 5 edited, 1 added, 1 removed
    What changed in the outcomes
    • EditedPupil Diameter - Change fromFrom Day 1 Pre-Dose BaselineTime frame: Day 1 post-dose and Days 4, 8, and 15
    • EditedMean Mesopic Contrast Sensitivity withWith Glare at 1 or More Frequencies atof 1.5, 3, 6, 12, and 18 Cycles Per Degree, Measured withWith the HACSS Methodology in LogCS Scale - Change fromFrom Day 1 Pre-Dose BaselineTime frame: Day 1 post-dose and Days 4, 8, and 15 → 15 Days
    • EditedMesopic Contrast Sensitivity withoutWithout Glare at 1 or More Frequencies at 1.5, 3, 6, 12, and 18 Cycles Per Degree, Measured withWith the HACSS Methodology in LogCS Scale - Mean Change fromFrom Day 1 Pre-Dose BaselineTime frame: Day 1 post-dose and Days 4, 8, and 15
    • EditedMesopic Distance High Contrast Visual Acuity (HCVA), Measured withWith Electronic Early Treatment Diabetic Retinopathy Study (eETDRS) Charts - Change fromFrom Day 1 Pre-Dose BaselineTime frame: Day 1 post-dose and Days 4, 8, and 15
    • EditedMesopic Distance Low Contrast Visual Acuity (LCVA), Measured withWith eETDRS Charts - Change fromFrom Day 1 Pre-Dose BaselineTime frame: Day 1 post-dose and Days 4, 8, and 15
    • AddedSubjective Evaluations of Vision (NEI Vision Function) at Follow-up (Day 32)Time frame: Day 32
    • Removedother outcomeSubjective Evaluations of Vision (NEI Vision Function) - Change from Day 15Time frame: Day 32
    + 3 other changes: verification date, registry notes and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT01703559
Lead sponsor
Opus Genetics, Inc
Responsible party
Sponsor
First posted
Oct 10, 2012
Start date
Sep 9, 2011
Primary completion
Apr 16, 2012
Completion
Apr 30, 2012
Results posted
Oct 8, 2026
Last update
Oct 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Phentolamine

Start the discussion